Provided by Tiger Trade Technology Pte. Ltd.

Vivos Therapeutics

0.1816
+0.01146.70%
Post-market: 0.1759-0.0057-3.14%17:48 EDT
Volume:2.65M
Turnover:468.16K
Market Cap:3.65M
PE:-0.10
High:0.1825
Open:0.1647
Low:0.1647
Close:0.1702
52wk High:3.82
52wk Low:0.1575
Shares:20.12M
Float Shares:19.87M
Volume Ratio:0.20
T/O Rate:13.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8267
EPS(LYR):-2.0700
ROE:-8585.26%
ROA:-56.19%
PB:-0.74
PE(LYR):-0.09

Loading ...

Vivos Therapeutics Reports Full Year 2025 Financial Results

THOMSON REUTERS
·
Apr 16

Vivos Therapeutics to report full-year results, host investor conference call

Reuters
·
Apr 15

Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call

GlobeNewswire
·
Apr 15

Vivos Therapeutics says V-Co Investors 3 files initial beneficial ownership statement

Reuters
·
Apr 11

Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners

GlobeNewswire
·
Apr 07

Broadcom, Vivos Therapeutics And 3 Stocks To Watch Heading Into Monday

Benzinga_recent_news
·
Apr 06

Vivos Therapeutics Completes Private Placement to Bolster Liquidity

TIPRANKS
·
Apr 04

Vivos Therapeutics raises $2.3 million in private placement with Seneca affiliate

Reuters
·
Apr 04

Why Did Vivos Therapeutics (VVOS) Stock Jump Over 21% After Hours

Benzinga_recent_news
·
Apr 03

Major Investor Quietly Ramps Up Stake in Vivos Therapeutics

TIPRANKS
·
Apr 03

Michael C. Skaff reports $1.8 million Vivos Therapeutics common share acquisition

Reuters
·
Apr 03

Vivos Therapeutics Delays Annual Filing Amid Expansion

TIPRANKS
·
Apr 01

Vivos Therapeutics delays filing annual report, cites Sleep Center of Nevada acquisition review

Reuters
·
Apr 01

Vivos Therapeutics Files for Non-Timely 10-K - SEC Filing

THOMSON REUTERS
·
Apr 01

Vivos Therapeutics: Anticipates Its REV Increased by Over 15% for Year Ended Dec 31, 2025

THOMSON REUTERS
·
Apr 01

Vivos Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Reuters
·
Mar 28

Vivos Therapeutics Inc - Expects to Become Cash Flow Positive During Fiscal Year 2026

THOMSON REUTERS
·
Mar 26

Vivos Therapeutics Inc - Announces Cost Reduction Initiatives Including Reduction in Force and Vendor Changes

THOMSON REUTERS
·
Mar 26

Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status Across Multiple Commercial Health Insurers and Medicare in Key Nevada Market

GlobeNewswire
·
Mar 26

Clinical study links narrow dental arches and high palates to obstructive sleep apnea severity, Vivos says

Reuters
·
Mar 19